Increased COVID-19 mortality in patients with schizophrenia: A retrospective study in Brazil.

Autor: Costa DFB; Post Graduation Program of Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, Brazil., Rossignoli P; Pharmaceutical Assistance Coordination, Health Secretary of Paraná, Curitiba, Brazil., Pontarolli DRS; Pharmaceutical Assistance Coordination, Health Secretary of Paraná, Curitiba, Brazil., Junior PC; Epidemiological Vigilance, Health Secretary of Paraná, Curitiba, Brazil., Assolari CL; Epidemiological Vigilance, Health Secretary of Paraná, Curitiba, Brazil., Nasr AMLF; Epidemiological Vigilance, Health Secretary of Paraná, Curitiba, Brazil., de Carvalho DS; Post Graduation Program of Collective Health, Federal University of Paraná (UFPR), Curitiba, Brazil., Gadelha A; Department of Psychiatry, Federal University of São Paulo (UNIFESP), São Paulo, Brazil., Massuda R; Post Graduation Program of Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, Brazil; Department of Psychiatry, Federal University of Paraná (UFPR), Curitiba, Brazil. Electronic address: rfmassuda@ufpr.br.
Jazyk: angličtina
Zdroj: Schizophrenia research [Schizophr Res] 2024 Sep; Vol. 271, pp. 200-205. Date of Electronic Publication: 2024 Jul 20.
DOI: 10.1016/j.schres.2024.07.036
Abstrakt: The risk that COVID-19 poses for mortality risk in individuals with schizophrenia in low- and middle-income countries has only been the subject of a few studies. In this retrospective study, we examined the standardized mortality ratio (SMR), by age group and sex, in a cohort of patients diagnosed with schizophrenia (n = 20,417), with second-generation antipsychotics, in a South Brazilian State database (Paraná-Brazil). We performed a linkage with the Brazilian Mortality Information System database between 2020 and 2021. We also assessed in a logistic regression how clozapine could affect COVID-19 mortality controlling by sex, age, and presence of obesity. A secondary analysis was to compare mortality with SMR due to COVID-19 in individuals with and without obesity. Compared to the State population (8,850,682 individuals), those with schizophrenia had more than two times greater risk of dying from COVID-19 (SMR = 2.21, 95 % CI: 1.90-2.55). Between the ages of 16 and 29, their risk is more than ten times higher than the state population (SMR = 10.18, 95 % CI: 4.73-19.33). Obesity showed an almost twofold risk of dying from COVID-19 in the patient's group (OR = 1.89, 95 % CI: 1.39-2.57). Clozapine was not found as a protector or a risk factor for COVID-19 mortality. In Brazil, a middle-income nation, people with schizophrenia are more likely to die prematurely from COVID-19. The burden of schizophrenia is higher in younger and in patients with obesity.
Competing Interests: Declaration of competing interest AG has been a consultant/advisor and/or has received honoraria from Aché, Daiichi-Sankyo, Torrent, Cristalia, and Janssen. DFBC has been a consultant/advisor and/or has received honoraria from Torrent. All other authors declare no competing interests. RM has been a consultant/advisor and/or has received honoraria from Daiichi-Sankyo and Janssen.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: